Completed PHASE1 INTERVENTIONAL 4-arm NCT02169414

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

Sponsor: Bial - Portela C S.A.

Conditions Parkinson's Disease (PD)

Interventions BIA 9-1067 25 mg BIA 9-1067 5 mg Placebo levodopa/benserazide 100/25 mg levodopa/carbidopa 100/25

Updated 5 times since 2017 Last updated: Nov 19, 2015 Started: Feb 28, 2010 Primary completion: Jul 31, 2010 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Parkinson's Disease (PD) and is currently completed. Bial - Portela C S.A. leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bial - Portela C S.A.

Data source: Bial - Portela C S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rennes, France